(Q41615240)

English

The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma

scientific article published on 4 August 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma (English)

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

Charles G. Drake

12

object named as

Charles G Drake

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

Tracee L. McMiller

2

object named as

Tracee L McMiller

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

Suzanne L. Topalian

15

object named as

Suzanne L Topalian

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

13

object named as

Drew M Pardoll

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

14

object named as

Janis M Taube

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

author name string

Maria Libera Ascierto

1

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

Alan E Berger

3

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

Ludmila Danilova

4

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

Robert A Anders

5

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

George J Netto

6

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

Haiying Xu

7

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

Theresa S Pritchard

8

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

Jinshui Fan

9

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

Chris Cheadle

10

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

Leslie Cope

11

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

publication date

4 August 2016

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

Cancer Immunology Research

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

4

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

9

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

726-733

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584610

6 June 2018

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584610

6 June 2018

Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584610

6 June 2018

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584610

6 June 2018

Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584610

6 June 2018

Immune checkpoint blockade: a common denominator approach to cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584610

6 June 2018

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584610

6 June 2018

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584610

6 June 2018

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584610

6 June 2018

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584610

6 June 2018

Comprehensive molecular characterization of clear cell renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584610

6 June 2018

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584610

6 June 2018

Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584610

6 June 2018

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584610

6 June 2018

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584610

6 June 2018

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584610

6 June 2018

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584610

6 June 2018

The genetic basis of kidney cancer: a metabolic disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584610

6 June 2018

Glucuronidation and the UDP-glucuronosyltransferases in health and disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584610

6 June 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584610

6 June 2018

Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584610

6 June 2018

Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/27491898

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor-specific cytolysis by lymphocytes infiltrating human melanomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/27491898

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/2326-6066.CIR-16-0072

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41615240&oldid=1925087501"